Transaktionen anzeigen
Healthcare | TMT

HD Clinical Ltd. has been acquired by NEXUS AG

NEXUS AG has acquired HD Clinical Ltd. Through this acquisition, NEXUS has gained a recognized and internationally active team of experts in structured diagnostic reporting and image processing. This will provide new regional access, strengthening its strong European market position in software, particularly for internal medicine.

HD Clinical was founded in 2005 by a group of clinicians to build an electronic clinical record system starting from departmental requirements and delivering management data derived from real-world patient information. This was a departure from the historic top-down approach of electronic patient record (EPR) systems, which were essentially upgraded patient administration systems with ‘one-size-fits-all’ clinical functionality bolted on. For 17 years, HD Clinical has been delivering digital clinical solutions to healthcare organizations around the world. The company’s solutions are used by 146 organizations across the globe, joining up healthcare organizations and hospital departments to improve the patient experience. The HD Clinical approach is designed to capture maximum engagement from clinical teams by meeting their needs and recognizing the specific requirements of each specialty. Their software and hardware are designed by their in-house team in the HD Clinical UK office.

Nexus AG provides innovative software solutions that allow users at healthcare facilities to focus on what really matters. Their goal is to offer all departments in hospitals, psychiatric wards and rehabilitation and residential institutions the best solution to the challenges they face every day.

Oaklins Evelyn Partners, one of Oaklins’ member firms in the UK, acted as lead the advisor to HD Clinical’s shareholders on the sale of the business. After winning a competitive pitch process, the team advised on all aspects of the transaction, from initial buyer research and preparation for sale to the preparation of marketing documents, leading negotiations and buyer meetings, managing due diligence and general project management throughout the deal.

Art der transaktion
BETEILIGTE PARTEIEN
“The team at Oaklins Evelyn Partners was able to successfully navigate us through what turned out to be an incredibly complex and challenging transaction process. The level of attention, communication and availability exceeded our expectations. The Oaklins team which led the deal was invaluable to us and provided the required support and advice while keeping the momentum of the deal going. Their drive and determination to get the right deal for the shareholders was exceptional. I look forward to working with the team again in the, hopefully, not too distant future.”

Dr Clive Layton

Founder, HD Clinical

Sprechen Sie mit dem Deal-Team

Prashant Dhokia

Manager
Cambridge, Großbritannien
Oaklins Evelyn Partners

Transaktionen

Xiel Limited has been acquired by MIS Healthcare
Private Equity | Healthcare

Xiel Limited has been acquired by MIS Healthcare

MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.

Mehr erfahren
Die Bayer AG hat eine Übernahmevereinbarung mit Cara Care geschlossen
Healthcare | TMT

Die Bayer AG hat eine Übernahmevereinbarung mit Cara Care geschlossen

Die Bayer AG, bekannt für vielfältige Innovationen in den Bereichen Gesundheit und Life Science, hat die Übernahme von Cara Care (HiDoc Technologies GmbH) vereinbart, für die im Oktober 2024 ein Insolvenzverfahren eröffnet worden war. Cara Care, eine innovative digitale Gesundheitsplattform und offizielle DiGA, passt perfekt zu Bayers strategischem Fokus auf digitale Gesundheit und die Erweiterung seines Lösungsportfolios. Der Abschluss der Transaktion wird für das Frühjahr 2025 erwartet.

Mehr erfahren
Grupo Veta 2017 S.L. has been acquired by MSA Mizar
Private Equity | Business Support Services | Financial Services | TMT

Grupo Veta 2017 S.L. has been acquired by MSA Mizar

The Franco-Belgian fund Kartesia has sold Grupo Veta 2017 S.L. to the Italian group MSA Mizar. Kartesia, the main shareholder of Veta+ together with its founding partner, has sold 100% of the capital. For MSA Mizar, this transaction represents the consolidation of its presence in Spain, the entry into the multi-risk claims management market and the opportunity to apply Veta+’s expertise to other European markets.

Mehr erfahren